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Background: Antibiotic-impregnated central venous catheters (CVCs) reduce the risk of 23 
bloodstream infections (BSIs) in patients treated in paediatric intensive care units (PICUs). 24 
However, it is unclear if they are cost-effective from the perspective of the National Health 25 
Service (NHS) in the UK. 26 
Methods: Economic evaluation alongside the CATCH trial (ISRCTN34884569) to estimate 27 
the incremental cost effectiveness ratio (ICER) of antibiotic-impregnated (rifampicin and 28 
minocycline), heparin-bonded and standard polyurethane CVCs. The 6-month costs of CVCs 29 
and hospital admissions and visits were determined from administrative hospital data and 30 
case report forms. 31 
Results: BSIs were detected in 3.59% (18/502) of patients randomized to standard, 1.44% 32 
(7/486) to antibiotic and 3.42% (17/497) to heparin CVCs. Lengths of hospital stay did not 33 
differ between intervention groups. Total mean costs (95% confidence interval) were: 34 
£45,663 (£41,647 to £50,009) for antibiotic, £42,065 (£38,322 to £46,110) for heparin, and 35 
£44,503 (£40,619 to £48,666) for standard CVCs. As heparin CVCs were not clinically 36 
effective at reducing BSI rate compared to standard CVCs, they were considered not to be 37 
cost-effective. The ICER for antibiotic versus standard CVCs, of £54,057 per BSI avoided, 38 
was sensitive to the analytical time horizon. 39 
Conclusions: Substituting standard CVCs for antibiotic CVCs in PICUs will result in reduced 40 
occurrence of BSI but there is uncertainty as to whether this would be a cost-effective 41 
strategy for the NHS. 42 
Key words: 43 
Cost-effectiveness analysis, bloodstream infection, central venous catheter, paediatric 44 
intensive care, antibiotic, heparin 45 




Central venous catheters (CVCs) are a large yet potentially avoidable cause of health-care 48 
associated infections in hospitals. In paediatric intensive care units (PICUs), catheter-related 49 
bloodstream infections (BSIs) occur in 3% to 8% of all CVC insertions [1]. BSIs are 50 
associated with increased morbidity, mortality, lengths of hospital stay and healthcare costs 51 
[2,3]. Since between 40% and 60% [4] of the 16,000 annual admissions to English PICUs [5] 52 
require CVCs, BSIs represent a major burden to patients and the National Health Service 53 
(NHS) [3,6]. 54 
The incidence of BSI in adults may be reduced with CVCs impregnated with antibiotics, 55 
antibacterial agents or heparin. These are recommended for use in adults at highest risk of 56 
BSI [7], but evidence in children is lacking [8]. CVC use in children presents a greater 57 
theoretical risk of BSI owing to the narrower lumens within which blood may thrombose more 58 
readily. The CATheter Infections in Children (CATCH) trial (NCT01029717) was a pragmatic, 59 
three-arm randomized controlled trial aimed to determine the clinical and cost-effectiveness 60 
of antibiotic or heparin CVCs compared with standard CVCs in children requiring intensive 61 
care. Both heparin-bonded and antibiotic-impregnated CVCs prevent biofilm formation which 62 
prevents bacterial colonisation. Heparin inhibits thrombus formation and heparin-bonded 63 
CVCs use benzalkonium chloride as an anti-infective bonding agent. The primary analyses 64 
of CATCH, however, showed no effect of impregnated compared with standard CVCs [9,10]; 65 
but secondary analyses revealed antibiotic CVCs to be superior to heparin CVCs with a 66 
hazard ratio (HR) for time to first BSI of 0.42 (95% CI, 0.19 to 0.93), and to standard 67 
polyurethane CVCs (HR 0.43; 95% CI 0.20 to 0.96). Heparin CVCs were no different from 68 
standard (HR 1.04; 95% CI, 0.53 to 2.03). 69 
As impregnated CVCs are more expensive than standard, decisions on their broader use 70 
within the NHS requires evidence of their cost-effectiveness. Existing economic analyses are 71 
limited in their applicability to the PICU setting in the UK as they relate to adult populations 72 
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and, with one exception [1], apply to different healthcare systems (Australia [11], Germany 73 
[12] and the USA [13-15]). These studies indicate, however, that antibiotic-impregnated 74 
CVCs are associated with improved health outcomes and are cost saving. 75 
Previous economic evaluations are reliant on modelled costs and consequences of BSI 76 
using data from a range sources, often observational studies. As such, they rely on assumed 77 
attribution of hospital lengths of stay (the main cost driver) and mortality to BSI. The 78 
economic evaluation which adopted an NHS cost perspective assumed catheter-related 79 
BSIs increase the length of hospital stay by 6 additional days in intensive care units (ICU) 80 
and 5 additional days in a general medical ward [1]. A US cohort study of 1,339 paediatric 81 
cases of catheter-related BSI matched to controls by propensity-score, identified a higher 82 
mean attributable length of stay of 19 days [16]. While this is comparable with the 21 days 83 
excess length of stay estimated for BSI in paediatric haematology/oncology patients [17], 84 
studies of this nature are based on retrospective observational data and are prone to bias. 85 
Patients who are more ill are more likely to develop BSI, making it difficult to separate the 86 
contribution of BSI to excess length of stay from the underlying condition. 87 
The aim of the present study was to assess the cost-effectiveness of antibiotic and heparin 88 
CVCs relative to commonly used standard polyurethane CVCs in a UK PICU setting using 89 
data collected as part of the CATCH randomized controlled trial.  90 




Design and results of CATCH 93 
CATCH recruited 1,485 children <16 years who were admitted to any of 14 PICUs in 94 
England and who were expected to require a CVC for ≥3 days. Children were randomized 95 
equally to receive heparin-bonded, antibiotic-impregnated (rifampicin and minocycline) or 96 
standard polyurethane CVCs. The intervention was blinded to everyone except the clinicians 97 
responsible for inserting the catheter. The primary outcome was the time to first BSI 98 
occurring between 48 hours after randomization and 48 hours after CVC removal. This 99 
occurred in 3.59% (18/502) children randomized to standard CVC, 1.44% (7/486) to 100 
antibiotic and 3.42% (17/497) to heparin CVCs. In the primary analysis, impregnated CVCs 101 
(antibiotic and heparin) were no more effective than standard CVCs (HR 0.71; 95% CI 0.37, 102 
1.34). Antibiotic CVCs were superior to standard CVCs in secondary analysis (HR 0.43; 103 
0.20, 0.96) but heparin CVCs were not (HR 1.04; 0.53, 2.03). There were no differences 104 
between intervention groups in other outcomes, including time to thrombosis, 30-day 105 
mortality, or antibiotic resistance (minocycline or rifampicin). Trial results are presented in full 106 
elsewhere [9,10]. 107 
The CATCH trial is registered with the ClinicalTrials.gov (Trial registration: NCT01029717 108 
Registered 9 December 2009), and was conducted in accordance with the recommendations 109 
of the Research Ethics Committee for South West England, with prospective or deferred 110 
written informed consent obtained from all subjects in accordance with the Declaration of 111 
Helsinki. The protocol was approved by the Research Ethics Committee for South West 112 
England (reference number 09/H0206/69), and is available at 113 
www.nets.nihr.ac.uk/projects/hta/081347. 114 
Economic evaluation 115 
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We conducted a cost-effectiveness analysis as it is not possible to estimate health utilities in 116 
children in a PICU setting [18]. While this precluded any evidence on allocative efficiency, it 117 
allowed for an assessment of technical efficiency for selecting the most cost-effective CVC 118 
for reducing the occurrence of BSIs.  119 
Resource use 120 
The economic analysis adopted the perspective of the NHS in England, with resource use 121 
measurement focused on the principal cost drivers, which were PICU, High Dependency 122 
Unit (HDU) and ward stays (including readmissions), outpatient clinic visits, Accident and 123 
Emergency (A&E) admissions and the costs of the CVCs. The 6-month time horizon of the 124 
base-case analysis was chosen to include the costs associated with managing BSIs and 125 
associated complications.  Shorter time horizons were explored in sensitivity analyses. 126 
Patients’ use of hospital services were obtained from trial case report forms (CRF), Hospital 127 
Episode Statistics (HES), the Paediatric Intensive Care Audit Network (PICANet), and 128 
hospital Patient Administration Systems (PAS). CRFs were accessed for data on dates of 129 
hospital discharge, transfer to other hospitals and CVC removal. HES data on Healthcare 130 
Resource Groups (HRGs) corresponding to the type of care patients receive at a ward-level, 131 
outpatient visits and A&E admissions, were accessed from NHS Digital [19]. We accessed 132 
the PICANet dataset [20] for the National Schedule of Reference Cost HRGs for HDU and 133 
ICU stays [21], and for verifying the dates of hospital admission, transfer and discharge. The 134 
finance offices of each participating hospital provided data from Patient Administration 135 
Systems (PAS) on patients’ lengths of stay in ICUs and wards, and on relevant HRGs. 136 
These were used to supplement data that were otherwise missing from other sources. 137 
Costs analysis 138 
HRGs reflect NHS hospital payments for patients’ use of hospital services. Unit costs from 139 
the 2012-13 National Schedule of Reference Costs [21] were applied to all HRG codes; the 140 
most significant being those associated with PICU, Neonatal Intensive Care Unit (NICU) and 141 
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HDU (Table 1).  Basic HDU (XB07Z) or ICU (XB05Z) codes were applied in the 10% of 142 
cases where HRG codes were missing.  143 
Unit costs of ward, outpatient and A&E attendances are presented in the Supplementary 144 
Appendix Tables 1 to 3. Any missing HRGs from HES or PAS data were replaced with ward 145 
costs based on bed-day rates provided by hospital finance offices (Supplementary Appendix 146 
Table 4). Bed-day rates were also applied to unassignable HRG codes appearing in the HES 147 
and PAS data, but overall, bed-day rates were used to cost less than 1% of admissions. 148 
Catheter list prices were provided by the supplier (Cook Medical, Bloomington, IN, USA). 149 
The costs of care for the 6-months prior to randomization were calculated from HES and 150 
PICANet data. Given that HRGs relate to episodes of care, we calculated patient costs for 151 
the 6-months following randomization according to: 152 
Cost = (N/n+N) x (ward cost + PICU cost + HDU cost) 153 
+ (outpatient costs + A&E costs + CVC costs) 154 
Where n and N are the number of days patients were hospitalised prior to, and following 155 
randomization, respectively. 156 
Patients’ use of healthcare resources and total costs were calculated for the intention to treat 157 
population, and summary statistics were generated by intervention group.  158 
Outcomes 159 
The health outcome for the cost-effectiveness analysis was the presence of a first BSI. 160 
These were defined in CATCH by a positive blood culture from a sample that was clinically 161 
indicated and taken more than 48 hours after CVC insertion and up to 48 hours after CVC 162 
removal [9]. 163 
Incremental analysis 164 
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Each CVC was ranked in order of decreasing effectiveness and dominated interventions 165 
(those which are less effective or ineffective) or extendedly dominated interventions 166 
eliminated. The incremental cost effectiveness ratio (ICER) was calculated for remaining 167 
CVCs as the difference in the means of total costs divided by the difference in the proportion 168 
of bloodstream infections. 169 
Uncertainty analysis 170 
Bias-adjusted 95% central ranges for differences in costs and BSI were calculated from 171 
10,000 replicate bootstrap analyses. The joint uncertainty in costs and BSI was depicted in a 172 
cost-effectiveness acceptability curve (CEAC) which presented the probability of CVCs being 173 
cost effective for different threshold willingness to pay for each BSI averted [22]. 174 
Uncertainty in total costs was further assessed by adjusting for the contribution of baseline 175 
factors to overall variability [23]. 176 
Sensitivity analysis 177 
Given the dependency of costs and therefore the ICER on the analytic time horizon, a 178 
sensitivity analysis was performed in which costs were limited to those incurred during the 179 
index hospitalization (that is, excluding any re-admissions that may have occurred over the 180 
6-month period).  181 
Regression analysis 182 
Regression analyses were performed to control for possible baseline imbalances between 183 
intervention groups [23] and, by including a variable to representing the presence of a BSI, 184 
to estimate the value of healthcare resources associated with the management of BSI. The 185 
following pre-specified variables were tested for their independent associations with total 186 
costs: Age, body weight, 6-month pre-randomization costs (all log-transformed), gender, pre-187 
existing CVC 72 hours prior to randomization, health status before PICU admission, reason 188 
for admission (cardiovascular, endocrine or metabolic, infection, neurological, oncology, 189 
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respiratory, trauma, other), suspected infection at randomization, immune compromised, 190 
positive blood culture within 72 hours prior to randomization, numbers of devices in situ, and 191 
admission type (elective or emergency).  Where data were missing, we assumed: patients to 192 
be healthy (n=1), not immunocompromised (n=19) and no positive blood culture (n=5). 193 
Missing data for weight (n=2) were imputed with the mean (11.95 kg). 194 
Variables that were significant at the 5% level were included using a stepwise approach in 195 
multivariable generalized linear models (GLMs) that were specified using a combination of 196 
families (e.g. gamma and poisson) and links (e.g. log, square root and identity). Modified 197 
Park’s test and Akaike Information Criterion were used to assess GLM goodness of fit but 198 
were inconclusive. The identity link function performed best according to the Pearson 199 
Correlation, Pregibon Link and the Modified Hosmer and Lemeshow tests. We therefore 200 
specified an ordinary least squares regression based on the comparatively large sample size 201 
which guaranteed near-normality of sample means [24]. 202 
All analyses were performed using STATA Version 10, and the economic analysis was 203 
reported according to the Consolidated Health Economic Evaluation Reporting Standards 204 
(CHEERS) statement [25]. 205 




Resource use and costs 208 
Cost data were available for all patients. Hospital ICU/HDU length of stay and total costs 209 
were comparable between intervention groups during the 6-months prior to randomization. 210 
In the 6-months following randomization, patients randomized to antibiotic-impregnated 211 
CVCs were in PICU for a mean of 10.8 days (95% CI, 9.3 to 12.4), compared with 9.9 days 212 
(95% CI, 8.6 to 11.4) for those randomized to heparin-bonded CVC and 10.5 days (95% CI, 213 
9.2 to 11.9) for standard CVCs (Table 2). Mean durations of hospitalisation were 34.8 days 214 
(95% CI, 31.2 to 38.5) for antibiotic-impregnated CVC, 31.4 days (95%CI, 28.2 to 34.7) for 215 
heparin-bonded CVC and 31.7 (95% CI, 28.8 to 34.7) for the standard CVC group. Six 216 
HRGs (from a total of 349) relating to congenital or other cardiac surgery and lower 217 
respiratory tract disorders, accounted for 50% of ward costs. 218 
Mean 6-month costs were £44,503 (median £28,952; range £1,786 to £360,983; 95% CI, 219 
£40,619 to £48,666) for standard CVC, £45,663 (median £29,793; range £2,189 to 220 
£442,365; 95% CI, £41,647 to £50,009) for antibiotic-impregnated CVC, £42,065 (median 221 
£27,621; range £2,638 to £382,431; 95% CI, £38,322 to £46,110) for heparin-bonded CVC 222 
(Table 3).  Costs were not significantly different by CVC group over the 6-month timeframe. 223 
Variables tested for the cost regression were evenly balanced between intervention groups 224 
[8].  The residual variability in total cost could be explained, in part, by the following 225 
significant explanatory variables: age (in days), 6-month pre-randomization costs (both log-226 
transformed), health status at randomization, reason for admission, immune status, and 227 
admission type (elective or emergency). The adjusted incremental costs associated with 228 
antibiotic CVCs, in relation to standard CVCs, were £1,220 (95% CI, -£4,332 to £6,773), and 229 




Seven patients from 486 randomized to antibiotic CVCs experienced a BSI, compared with 232 
17/497 in the heparin CVC group and 18/502 in the standard CVC group.  A statistically 233 
significant absolute risk differences was found only for antibiotic versus standard CVCs (-234 
2.15%; 95% CI, -4.09 to -0.20). Heparin CVCs were not clinically effective with a risk 235 
difference of -0.17% (95% CI, -2.45 to 2.12) versus standard CVC. 236 
Value of healthcare resources associated with BSI 237 
Patients who had a BSI (n=42) experienced 6.5 more days (95% CI, 1.4 to 11.6) in PICU 238 
than those with no BSI (n=1,443), and 15.1 additional total days (95% CI, 4.0 to 26.2) of 239 
hospitalization. The mean 6-month costs for patients with a BSI was £60,481 (95% CI, 240 
£47,873 to £73,809) compared to £43,578 (95% CI, £41,185 to £45,970) for those without; a 241 
difference of £17,263 (95% CI, -£3,076 to £31,450). The adjusted difference in mean costs 242 
was £10,975 (95% CI, -£2,801 to £24,751).  243 
Incremental and uncertainty analysis 244 
Heparin CVCs were not clinically effective when compared to standard CVC, and are more 245 
expensive, and so cannot be cost-effective by the same measure of BSI. The ICER for 246 
antibiotic-impregnated versus standard CVCs was £54,057 per BSI averted (Table 4). 247 
The probabilities of antibiotic CVCs being cost-effective at thresholds of £10,000, £50,000 248 
and £100,000 per BSI averted, were 0.38, 0.49 and 0.62, respectively (Figure 1). There is a 249 
probability of 0.650 for standard CVCs dominating antibiotic CVCs. 250 
Sensitivity analysis 251 
Considering only the index hospitalization, total costs in the antibiotic CVC group were 252 
£33,073 (95% CI, £30,047 to £36,337) compared to £32,245 (95% CI, £29,013 to £35,823)  253 
in the heparin CVC group and £35,165 (95% CI, £31,864 to £38,670) in the standard CVC 254 
group. Antibiotic CVCs therefore dominated standard CVC with a difference of 2.15% in the 255 




The results of the base-case analysis indicate that heparin-bonded CVCs are not cost-258 
effective while the incremental cost-effectiveness ratio of antibiotic-impregnated CVCs 259 
versus standard CVCs is £54,057 per BSI averted. However, there is considerable 260 
uncertainty in this estimate. Restricting costs to the index hospital stay resulted in an ICER 261 
of £97,543 saved per BSI averted for antibiotic compared to standard CVCs. Antibiotic CVCs 262 
are highly cost-effective when considering costs accruing over comparable periods to 263 
events. 264 
The economic analysis benefits from having been designed and executed as an integral part 265 
of a pragmatic clinical trial that provided an unbiased comparison of CVCs in the context of 266 
current practice in 14 UK PICUs.  The cost-effectiveness analysis was conducted to 267 
accepted methodological standards of trial-based economic evaluations [26]. Patient-level 268 
HES data were used to reflect NHS payments to hospitals for their services, and we 269 
exploited different sources to ensure a complete dataset.  270 
However, there are limitations to the analysis. First, the CATCH trial was not powered to 271 
demonstrate statistically significant differences in effectiveness or costs among each of the 272 
three types of CVCs. However, differences in the rates of BSI were pre-specified in a 273 
secondary analysis, and a lack of a difference in costs between intervention groups is less 274 
relevant in the context of net benefits [27]. The joint uncertainty in costs and BSI is 275 
considered in the CEAC which indicated antibiotic CVCs as having a probability of 0.35 of 276 
dominating standard CVCs. Despite not being effective at reducing BSI rates, the mean 277 
costs associated with heparin CVCs were lower than for either antibiotic or standard CVCs. 278 
This is likely to be explained by BSI being a rare event, with associated costs diluted in the 279 
overall costs of managing patients in intensive care. 280 
A second limitation was in our choice of economic outcome. The quality-adjusted life-year 281 
(QALY), which is the preferred measure of health outcome for cost-utility analyses [28], 282 
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could not be estimated in the study population [18]. The majority of trial participants (58%) 283 
were aged less than one year, and even if utilities were measured by proxy, these would be 284 
unreliable, especially in the context of intensive care. Using BSI averted as the denominator 285 
of the ICER calculation also fails to fully capture other possible consequences of BSI, 286 
including long term neurological defects, mortality, antibiotic resistance [29] and other 287 
adverse events [30]. While neurological outcomes were not monitored in CATCH, there were 288 
no differences in 30-day mortality for antibiotic versus standard (HR 0.96; 95% CI, 0.61 to 289 
1.51) or for heparin versus standard CVC (HR 0.65; 95% CI, 0.40 to 1.07). There were also 290 
no differences between intervention groups in microbial resistance to minocycline or 291 
rifampicin, or in adverse event rates [9,10]. 292 
In contrast to QALYs, where an explicit threshold range has been defined (£20,000 to 293 
£30,000 per QALY gained for most health technologies in the UK), there is no threshold for 294 
BSIs averted. Interpretation may therefore be dependent on previous economic evaluations, 295 
such as Shorr et al., [14] who considered US$9600 to be cost-effective, or assumptions 296 
concerning the impact of BSI on health. For instance, if BSIs are assumed to impair patients’ 297 
quality of life by a year, (i.e. 1 QALY decrement on average), then antibiotic CVCs may not 298 
be cost-effective. 299 
The choice of analytical time horizon represents a further limitation. Six months was selected 300 
to capture the costs of subsequent hospital readmissions and transfers to other hospitals. 301 
However, as the cost-effectiveness calculation considered only the first BSI, costs accrued 302 
over time with no corresponding change to the number of BSI (these all occurred within 30 303 
days). Consequently, the ICER continued to increase over time. 304 
Our estimates of the costs associated with the management of BSI are broadly in line with 305 
other economic evaluations [1]; however there are appreciable differences in our estimate of 306 
the ICER. Previous economic analyses indicated the dominance of antibiotic CVCs over 307 
standard CVCs. Possible explanations for this discrepancy are that model-based analyses 308 
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are based on a synthesis of data from disparate sources, require strong assumptions on the 309 
attribution of hospital lengths of stay and mortality to BSI and assume independence of the 310 
cost of managing BSIs and CVC type.   311 
In conclusion, the results of the economic evaluation indicate that replacing standard 312 
polyurethane CVCs with antibiotic-impregnated CVCs in PICUs will result in reduced rates of 313 
BSI. Given the low background rate of BSI, the variation in costs between CVCs and the 314 
sensitivity of the ICER to the time-horizon of analysis, it remains uncertain if antibiotic-315 
impregnated CVCs are cost-effective from a UK NHS perspective. However, given the focus 316 
of the evaluation, there is limited generalisability outside the UK to other payers, healthcare 317 
systems or jurisdictions. Our economic findings from CATCH add to evidence on the 318 
generalisability of trial participants in the UK, and on the cost implications of using antibiotic-319 
impregnated CVCs to the NHS [31]. 320 
  321 
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Table 1. Unit cost for intensive care and high dependency care, based on HRGs from the 474 
National Schedule of Reference Costs (2012-13) 475 
HRG 
code 











































Intensive ventilation with 









Invasive ventilation with 
single system failure or 
non-invasive ventilation 










monitoring than is 
usually available on 
an ordinary 
children’s ward, with 
higher than usual 
staffing levels 
Non-invasive ventilation 
(e.g. CPAP and BiPAP 














Since pediatric critical care facilities are 
centralized in a small number of hospitals 




transport teams are required to deliver clinical 





Care provided for 
babies who are the 
most unwell or 
unstable and have 
the greatest needs in 
relation to staff skills 
and staff to patient 
ratios 
Baby receives any form 
of mechanical 
respiratory support via a 
tracheal 
tube and/or parenteral 
nutrition. 
£1,118 
Abbreviations: ECMO extra-corporeal membrane oxygenisation, ECLS extracorporeal life 476 
support, VAD Ventricular assist devices, CPAP Continuous Positive Airway Pressure, BiPAP 477 
Bi-Level Positive Air Pressure, IV intravenous. 478 
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Table 2. Patients’ lengths of stay from randomization to 6-months (including readmissions), according to place and intensity of care and by 
intervention group.  
 Antibiotic CVC Heparin CVC Standard CVC 
Unit Mean 95% CI Mean 95% CI Mean 95% CI 
Days on ICU 10.79 9.28, 12.48 9.91 8.57, 11.44 10.50 9.17, 11.93 
Pediatric Critical Care, Intensive Care, 
ECMO/ECLS (XB01Z) 
0.30 0.07, 0.72 0.38 0.09, 0.80 0.40 0.17, 0.72 
Pediatric Critical Care, Intensive Care, Advanced 
Enhanced (XB02Z) 
0.16 0.09, 0.26 0.12 0.09, 0.15 0.16 0.10, 0.26 
Pediatric Critical Care, Intensive Care, Advanced 
(XB03Z) 
0.76 0.51, 1.05 0.61 0.43, 0.83 0.65 0.46, 0.87 
Pediatric Critical Care, Intensive Care, Basic 
Enhanced (XB04Z) 
2.30 1.92, 2.72 2.68 2.09, 3.44 2.75 2.14, 3.54 
Pediatric Critical Care, Intensive Care, Basic 
(XB05Z) 
6.96 5.65, 8.45 5.63 4.75, 6.59 6.40 5.42, 7.47 
Neonatal Critical Care, Intensive Care (XA01C) 0.29 0.10, 0.55 0.46 0.13. 1.03 0.11 0.04, 0.20 
Days on HDU 1.99 1.48, 2.62 1.59 1.28, 1.99 1.73 1.44, 2.05 
Pediatric Critical Care, High Dependency, 
Advanced (XB06Z) 
1.27 0.94, 1.70 1.08 0.80, 1.45 1.22 0.98, 1.49 
Pediatric Critical Care, High Dependency (XB07Z) 0.71 0.42, 1.16 0.51 0.40, 0.64 0.51 0.40, 0.64 
Days on ward 22.01 19.26, 24.80 19.84 17.40, 22.40 19.48 17.12, 21.94 
Total days in hospital 34.80 31.21, 38.48 31.35 28.18, 34.65 31.71 28.75, 34.81 
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Count of non-PICU/HDU inpatient HRGs       
Complex Congenital Surgery (EA24Z) 100  103  109  
Intermediate Congenital Surgery (EA25Z) 68  70  72  
Major Complex Congenital Surgery (EA23Z) 45  39  37  
Cardiac Conditions with complication and 
comorbidity (PA23A) 
109  102  74  
Lower Respiratory Tract Disorders without acute 
bronchiolitis with length of stay ≥1 day with 
complication and comorbidity (PA14C) 
95  78  105  
Implantation of Prosthetic Heart or Ventricular 
Assist Device (EA43Z) 
2  2  4  
Other inpatient HRGs 1103  1055  964  
Abbreviations: CVC central venous catheter, CI confidence interval, ICU Intensive care unit, ECMO extra-corporeal membrane oxygenisation, 




Table 3. Disaggregated and total costs (£) by intervention group from randomization to end of the six-month timeframe.  
 Antibiotic CVC Heparin CVC Standard CVC 
Unit (code) Mean 95% CI Mean 95% CI Mean 95% CI 
Pediatric Critical Care, Intensive Care 
ECMO/ECLS (XB01Z) 1358 310, 3159 1703 386, 3509 1796 723, 3156 
Advanced Enhanced (XB02Z) 388 207, 636 289 216, 371 395 228, 620 
Advanced (XB03Z) 1545 1031, 2124 1250 872, 1674 1318 933, 1752 
Basic Enhanced (XB04Z) 4861 4060, 5738 5675 4418, 7260 5822 4512, 7460 
Basic (XB05Z) 12,137 9855, 14,730 9822 8274, 11,489 11,159 9440, 13,025 
Neonatal Critical Care, Intensive Care 
(XA01C) 
325 113, 613 517 142, 1150 125 42, 225 
Pediatric Critical Care, HDU 
High Dependency, Advanced (XB06Z) 1709 1254, 2271 1450 1972, 1940 1629 1301, 1992 
High Dependency (XB07Z) 635 372, 1025 454 354, 567 456 356, 566 
Transportation (XB08Z) 1158 1022, 1293 1258 1109, 1413 1208 1068, 1353 
Sub-total (PICU/HDU/NICU)a 24,115 20,824, 27,764 22,417 19,429, 25,771 23,907 20,989, 27,049 
Inpatient stayb       
Complex Congenital Surgery (EA24Z) 3011 2445, 3593 2908 2363, 3481 3144 2565, 3753 
Intermediate Congenital Surgery (EA25Z) 2166 1670, 2699 1934 1470, 2440 2044 1583, 2545 
Major Complex Congenital Surgery 
(EA23Z) 
1865 1315, 2481 1915 1310, 2603 1466 1013, 1960 




Lower Respiratory Tract Disorders without 
acute bronchiolitis with length of stay ≥1 
day with complication and comorbidity 
(PA14C) 
858 593, 1157 668 454, 913 943 657, 1268 
Implantation of Prosthetic Heart or 
Ventricular Assist Device (EA43Z) 
273 0, 684 298 0, 762 548 103, 1155 
Other inpatient HRG costs 10,316 8616, 12,231 8803 7524, 10,106 9930 7860, 12,409 
Sub-total (inpatient) 19,766 17,934, 21,755 17,700 16,308, 19,182 18,814 16,649, 21,327 
A&E cost 89 76, 104 85 73, 99 91 78, 104 
Outpatient cost 1615 1412, 1838 1784 1496, 2109 1648 1453, 1871 
CVC cost 78 78, 78 78 78, 78 43 43, 43 
Total Cost (full 6 months) 45,663 41,647, 50,009 42,065 38,322, 46,110 44,503 40,619, 48,666 
 
a National Schedule of Reference Costs 2012-2013; bTop 6 (of 349) HRGs ranked by cost, together contributing 50% of overall inpatient cost, 
<1% taken from bed day rates. 
Abbreviations: CVC central venous catheter, CI confidence interval, ECMO extra-corporeal membrane oxygenisation, ECLS extracorporeal life 
support, HDU High dependence unit, PICU Pediatric intensive care unit, NICU Neonatal intensive care unit, HRGs Healthcare Resource 
Groups, A&E Accident and Emergency. 
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Table 4. Incremental analysis 
 Antibiotic CVC Heparin CVC Standard CVC 
Base-case analysis (6-month time horizon) 


























ICER (versus standard)  £54,057  
per BSI averted 
-a - 
Sensitivity analysis (index hospitalization) 


























ICER (versus standard)  -£97,543  
per BSI averted b 
-a - 
Values are means with 95% confidence intervals in parentheses. 
aAs heparin CVC was not deemed to be clinically effective in reducing BSI rates, it cannot be 
cost-effective by the same outcome measure 
Abbreviations: BSI bloodstream infection, ICER incremental cost effectiveness ratio, CVC 





Figure 1. Cost-effectiveness acceptability curve presenting the probability of antibiotic and 
standard CVCs being cost-effective for a given values of ceiling ratio expressed as cost per 
bloodstream infection (BSI) averted 
 
